Invention Grant
US07674579B2 Apoptosis-based evaluation of chemosensitivity in cancer patients
有权
基于细胞凋亡的癌症患者化学敏感性评估
- Patent Title: Apoptosis-based evaluation of chemosensitivity in cancer patients
- Patent Title (中): 基于细胞凋亡的癌症患者化学敏感性评估
-
Application No.: US10580170Application Date: 2004-11-26
-
Publication No.: US07674579B2Publication Date: 2010-03-09
- Inventor: Guillermo Mor
- Applicant: Guillermo Mor
- Applicant Address: US CT New Haven
- Assignee: Yale University
- Current Assignee: Yale University
- Current Assignee Address: US CT New Haven
- Agency: Cooley Godward Kronish LLP
- International Application: PCT/US2004/039650 WO 20041126
- International Announcement: WO2005/054814 WO 20050616
- Main IPC: C12Q1/70
- IPC: C12Q1/70 ; G01N33/53

Abstract:
Induction of apoptosis in target cells is a key mechanism by which chemotherapy induces cell killing. An in vitro system has been established for determining carboplatin and paclitaxel (Taxol) chemosensitivity of epithelial ovarian cancer cells, where measurements of caspase-3 activation are surrogate markers for activation of chemotherapy-induced programmed cell death. To validate the assay as a predictor of clinical chemotherapy-induced programmed cell death. To validate the assay as a predictor of clinical chemosensitivity in vitro apoptotic response were compared to the clinical response of the patients from whom the tumor cells were isolated. Caspase-3 activation in response to in vitro chemotherapy to both drugs was shown to have an 83% positive predictive value and a 71% negative predictive value. Markers of apoptosis such as caspase-3 activation can be quantitated and utilized to predict the clinical response to chemotherapy.
Public/Granted literature
- US20070275434A1 Apoptosis-Based Evaluation Of Chemosensitivity In Cancer Patients Public/Granted day:2007-11-29
Information query